Antoni Bayes-Genis
Antoni Bayes-Genis is an expert in Cardiology at Hospital Universitari Germans Trias i Pujol (Spain). As of October 2026, ScienceLeadR ranks Antoni Bayes-Genis in the top 1% of experts worldwide for Heart Failure, Cardiomyopathies and Myocardial Ischemia. Antoni Bayes-Genis has authored 1,375 publications, the most recent in 2026, and is an investigator in 37 clinical trials, 9 of them ongoing. SLR score: 6,021 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Public Health - Biochemistry - Internal Medicine
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1999 - 2026
Number : 1375
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Design and validation of a GMP-compliant manufacturing platform of extracellular vesicles from mesenchymal stromal cells. PMID 42926845 — cells, extracellular vesicles, mesenchymal stem cells, bioreactors, stromal cells | iScience | 2026 | 0 |
| Prognostic impact of moderate secondary mitral regurgitation after optimized medical therapy in heart failure. PMID 42888505 — mortality, incidence, heart failure, heart, echocardiography, therapeutics, mitral valve insufficiency, prognosis | ESC Heart Fail | 2026 | 0 |
| Telerehabilitation vs. centre-based cardiac rehabilitation after acute coronary syndrome: results of the pragmatic TELECOR randomized trial. PMID 42892836 — life style, hospitals, public, cardiac rehabilitation, rehabilitation, acute coronary syndrome, telerehabilitation, risk factors, heart disease risk factors | Eur Heart J Open | 2026 | 0 |
| Diagnostic Accuracy of NT-proBNP thresholds in Dyspneic Patients in the Emergency Department according to patients' characteristics: A Systematic Review and Meta-Analysis. PMID 42888496 — emergencies, heart failure, aged, obesity, emergency service, hospital | Eur J Heart Fail | 2026 | 0 |
| Long-Term Safety and Procedural Performance of an Interatrial Shunt for Heart Failure According to Ejection Fraction. PMID 42886087 — safety, hemorrhage, heart failure, heart, phenotype, heart failure, diastolic, drug-related side effects and adverse reactions, heart failure, systolic, therapeutics, atrial shunt | JACC Heart Fail | 2026 | 0 |
Clinical Studies 37
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
9 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| An open label extension (OLE) trial to evaluate long term safety and tolerability of pelacarsen (TQJ230) 2024-519870-38-00 — safety, cardiovascular diseases | Phase 3 | Not yet recruiting | 2026 |
| CLEOPATTRA A research study to look at the effects of treatment with a medicine called coramitug (NNC6019 0001) in people with heart failure due to ATTR amyloidosis 2024-518899-31-00 — heart failure, heart, prealbumin, amyloidosis, research, therapeutics, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis | Phase 3 | Recruiting | 2025 |
| 202301CPC Redefine HF 2023-508581-15-00 — mortality, safety, heart failure, heart, morbidity | Phase 3 | Recruiting | 2024 |
| A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure 2023-509706-30-00 — safety, heart failure, heart | Phase 3 | Recruiting | 2024 |
| EASi PROTKT A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes high blood pressure and cardiovascular disease 2025-521188-11-00 — diabetes mellitus, hypertension, safety, blood, cardiovascular diseases, blood pressure, diabetes mellitus, type 2 | Phase 3 | Recruiting | 2025 |
LeadR Networks
Main global connection map